Belimumab in systemic lupus erythematosus

Vilas-Boas, Andreia; Morais, Sandra A.; Isenberg, David

doi:10.1136/rmdopen-2014-000011

Cited by 27 publications

(22 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, it is the only approved biological for the treatment of systemic lupus erythematosus (SLE). [ 1 2 ]…”

mentioning

confidence: 99%

Belimumab in systemic lupus erythematosus

Srivastava

2016

Indian J Dermatol

View full text Add to dashboard Cite

Belimumab is the only approved biological agent for the treatment of systemic lupus erythematosus (SLE). It is a fully humanized IgG1γ monoclonal antibody directed against soluble B lymphocyte stimulator (BLyS). It is indicated as an add-on therapy for the treatment of adult patients with active, autoantibody-positive SLE, who are receiving standard therapy. Belimumab is generally well-tolerated, common adverse effects include infections, infusion reactions, hypersensitivity, headache, nausea, and fatigue. Psychiatric events including suicidal tendency, progressive multifocal leukoencephalopathy and malignancies too have been reported. Apart from SLE, the drug is also being tried for other autoimmune disorders.

show abstract

“…Currently, it is the only approved biological for the treatment of systemic lupus erythematosus (SLE). [ 1 2 ]…”

mentioning

confidence: 99%

Belimumab in systemic lupus erythematosus

Srivastava

2016

Indian J Dermatol

View full text Add to dashboard Cite

show abstract

“…Osteoporotic fractures are present in 20-26.1% of SLE patients and often an appropriate treatment is mandatory. At the same time, a large number of SLE patients suffer from many comorbidities and many organ involvement by the underlying disease [2,3,11,12,14]: therefore, they need a basic therapy able to ensure an absent or a low SLE disease activity, and at the same time an appropriate therapy for the osteopenia/osteoporosis. Nowadays, an increasing number of patients are treated with belimumab, due to its proven efficacy in reducing flares.…”

Section: Case Presentationmentioning

confidence: 99%

“…autoimmune disease. It may present with very different clinical manifestations, ranging from fatigue and mild skin rash to endstage renal failure [2,3]. A wide spectrum of clinical and serological findings often misleads and delays the diagnosis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report

Scarati

Parisi

Borrelli

et al. 2017

CMI

View full text Add to dashboard Cite

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by multisystemic involvement. Owing to multifactorial etiologies, low bone mineral density (BMD) osteoporosis (OP) and fragility fractures (FFx) have been very frequently documented in these patients. Appropriate treatments to minimize underlying immunologic disease activity remain mandatory, and the development of strategies to prevent and treat important complications as osteoporosis is needed.We present the clinical case of a female SLE patient treated simultaneously with belimumab (anti-BLyS) for the underlying disease, and denosumab (anti-RANKL) for concomitant severe osteoporosis. As these monoclonal antibodies have been recently introduced into the market, their combination has not been reported in literature yet. In this case, the combined administration proved a viable option for a SLE patient with osteoporosis and bisphosphonates contraindications.

show abstract

“…Both the European Medicines Agency (4) and the United States Food and Drug Administration (FDA) (3) approved belimumab for the treatment of SLE in 2011, thus becoming the first targeted therapy for this disease. Before belimumab, the last drug to be approved by the FDA for the treatment of SLE was hydroxychloroquine in 1955 (5).…”

Section: Introductionmentioning

confidence: 99%

One case of toxic epidermal necrolysis after treatment with belimumab in a patient with systemic lupus erythematosus

Duna¹,

Balanescu²,

Iosif³

et al. 2019

Ro J Rheumatol.

View full text Add to dashboard Cite

Belimumab is a human immunoglobulin G1-lambda-1 (IgG1-λ) monoclonal antibody that targets the soluble BLyS human protein, also known as B-cell activating factor (BAFF) approved for the treatment of systemic lupus erythematosus (SLE). Serious and sometimes fatal infections have been reported in patients receiving novel immunosuppressive agents, including belimumab. Thus, physicians should exercise caution when considering belimumab in patients with SLE. A 50-year-old woman with SLE presented with a severe, diffuse rash two months after initiating treatment with belimumab. A skin biopsy revealed epidermal necrolysis with keratinocyte detachment and apoptosis in the basal layer of the epidermis, suggestive for toxic epidermal necrolysis (TEN). Belimumab was discontinued and 500 mg of pulse IV methylprednisolone therapy every day for 3 days were administered, with resolution of the skin lesions in the following days. To the best of our knowledge, this is the first case of belimumab-associated TEN.

show abstract

Belimumab in systemic lupus erythematosus

Cited by 27 publications

References 50 publications

Belimumab in systemic lupus erythematosus

Belimumab in systemic lupus erythematosus

Safety of belimumab in association with denosumab in a patient affected by Lupus Erythematosus: a case report

One case of toxic epidermal necrolysis after treatment with belimumab in a patient with systemic lupus erythematosus

Contact Info

Product

Resources

About